Ora Pharm has acquired Helius Therapeutics for an undisclosed amount, marking a significant consolidation within New Zealand's medicinal cannabis sector. Helius Therapeutics, a New Zealand-owned company based in Auckland, is known for its focus on improving quality of life through safe and effective medicinal cannabis products. The company specialises in the cultivation, research, and manufacturing of GMP-certified medicinal cannabis products, aiming to provide locally-produced, quality options for New Zealanders.
This acquisition is strategically positioned to leverage Helius Therapeutics' established operational capabilities and expertise. Helius brings a robust infrastructure, including its Auckland facilities and a leadership team with extensive experience across pharmaceuticals, horticulture, marketing, operations, and finance. These assets are expected to integrate with Ora Pharm's operations, enhancing the combined entity's capacity for product development, manufacturing, and distribution within the domestic market. The move underscores a commitment to strengthening the supply chain and expanding the availability of high-quality medicinal cannabis.
The integration of Helius Therapeutics into Ora Pharm is anticipated to create a more comprehensive and efficient entity, poised to meet the evolving needs of patients in New Zealand. By combining resources and expertise, the acquisition aims to accelerate innovation and ensure a consistent supply of medicinal cannabis products. The unified organisation is expected to reinforce its position as a key player dedicated to advancing a naturally healthier society and improving the quality of life for New Zealanders who can benefit from medicinal cannabis.